Contineum Therapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Carmine N. Stengone
- Full Time Employees
- 51
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3565 General Atomics Court Suite 200 San Diego CA United States of America 92121
- IPO Date
- Apr 4, 2024
- CIK
- 0001855175
- Website
- contineum-tx.com
- Similar Companies
- Business
- Contineum Therapeutics, Inc. Contineum Therapeutics, Inc. (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company that discovers and develops novel oral small molecule therapies targeting neuroscience, inflammation, and immunology (NI&I) indications with significant unmet medical needs. The company advances a pipeline of internally developed drug candidates, including its lead wholly-owned asset PIPE-791, a brain-penetrant small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R), in clinical development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain; PIPE-307, a selective inhibitor of the muscarinic type 1 (M1) receptor in Phase 2 trials for relapsing-remitting multiple sclerosis (RRMS) and major depressive disorder (MDD) through a global license and development collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson Johnson & Johnson company; CTX-343, a peripherally restricted LPA1R antagonist in preclinical studies; and an undisclosed wholly-owned calpain inhibitor program. Contineum Therapeutics operates primarily in the United States, targeting patient populations with limited treatment options in NI&I diseases such as IPF affecting approximately 130,000 U.S. patients, various forms of multiple sclerosis, chronic pain including osteoarthritis and lower back pain, and depression. Founded in 2017 and headquartered at 3565 General Atomics Court, Suite 200, San Diego, California, the company formerly operated as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023 to reflect its expanded focus on NI&I disorders beyond core neuroscience. Recent developments include positive topline data from the PIPE-791 Phase 1b positron emission tomography (PET) trial in September 2025, demonstrating high brain receptor occupancy in healthy volunteers and PrMS patients with favorable safety; ongoing PIPE-307 Phase 2 VISTA trial in RRMS with topline data expected in Q4 2025; initiation of a global Phase 2 trial of PIPE-791 in IPF planned for Q4 2025; topline data anticipated from a PIPE-791 Phase 1b chronic pain trial in H1 2026; Johnson & Johnson-initiated Phase 2 Moonlight-1 trial of PIPE-307 in MDD recruiting since December 2024; strategic deferral of PIPE-791 PrMS and CTX-343 programs to extend cash runway into 2028; and $19 million raised via at-the-market offerings in Q3 2025.
Company News
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
Why Is Contineum Therapeutics Stock Falling Monday?
48,108 Contineum Therapeutics, Inc. $CTNM Shares Sold by Squarepoint Ops LLC
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 9.9% After Analyst Downgrade
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)